A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma

Cancer, Cancer - Melanoma
John McCann, MD

D’Amour Center for Cancer Care
3350 Main Street
Springfield MA 01199


Franklin Medical Center
164 High Street
Greenfield, MA


The purpose of this study is to  compare overall survival for patients receiving ipilimumab plus bevacizumab versus ipilimumab alone
Unresectable Stage III or Stage IV Melanoma; untreated or one previous treatment.
Betsy Lopez